Speciality Medicines IPO

Speciality Medicines Limited is a pharmaceutical company that focuses on selling and distributing high-end medicines. They deal with specialized treatments like oral and injectable drugs for complex chronic diseases. They don't just sell in India; they have a network covering over 35 countries, working with international partners to provide finished medical products.

Strengths:
The company has a very strong global footprint for a young firm, with products already registered or being registered in countries like Jordan, Ethiopia, Uganda, and Peru. One of their biggest strengths is their "Asset Light" model—they focus on marketing and distribution rather than heavy factory costs. They have shown impressive financial growth, with their Profit After Tax (PAT) jumping from ₹1.69 Cr in FY23 to ₹4.55 Cr in FY24. Their Return on Equity (ROE) is remarkably high at over 40%, showing they are very efficient at using shareholders' money to generate profit.

Growth:
The company is planning to use the IPO money to shift to the next level by setting up their own Research and Development (R&D) Center (budgeted at ₹13.31 Cr). This will help them create their own unique medical formulations. They are also investing heavily in international product registrations, which will open doors to more foreign markets. By expanding their distribution network across more Indian states and increasing their global reach, they are moving from being a simple distributor to a full-scale pharmaceutical player with its own research capabilities.